• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从一位马凡综合征患者的诱导多能干细胞(hiPSC)中生成 CRISPR/Cas9 校正的 hiPSC(NCCDFWi001-A-1),该患者的纤维连接蛋白 1(FBN1)基因中存在杂合 c.2613A>C 变异。

Generation of a CRISPR/Cas9-corrected-hiPSC (NCCDFWi001-A-1) from a Marfan syndrome patient hiPSC with a heterozygous c.2613A>C variant in the fibrillin 1 (FBN1) gene.

机构信息

State Key Laboratory of Cardiovascular Disease, Beijing Key Laboratory for Molecular Diagnostics of Cardiovascular Diseases, Diagnostic Laboratory Service, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

State Key Laboratory of Cardiovascular Disease, Center of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

出版信息

Stem Cell Res. 2021 Oct;56:102543. doi: 10.1016/j.scr.2021.102543. Epub 2021 Sep 20.

DOI:10.1016/j.scr.2021.102543
PMID:34592602
Abstract

Patient-specific hiPSCs (NCCDFWi001-A) were generated from a patient with Marfan syndrome carrying a compound heterozygous variant (c.684_736 + 4del, p.Pro228fs and c.2613A>C, p.Leu871Phe). Here, we used CRISPR/ Cas9 to correct the FBN1 c.2613A>C variant, which generated an hiPSC line (NCCDFWi001-A-1) that maintained normal karyotype, pluripotency markers and demonstrated potential for trilineage differentiation.

摘要

患者特异性诱导多能干细胞(NCCDFWi001-A)是从一位马凡综合征的复合杂合变异(c.684_736+4del,p.Pro228fs 和 c.2613A>C,p.Leu871Phe)的患者中产生的。在这里,我们使用 CRISPR/Cas9 来纠正 FBN1 c.2613A>C 变异,产生了一个维持正常核型、多能性标记物并表现出三系分化潜能的 hiPSC 系(NCCDFWi001-A-1)。

相似文献

1
Generation of a CRISPR/Cas9-corrected-hiPSC (NCCDFWi001-A-1) from a Marfan syndrome patient hiPSC with a heterozygous c.2613A>C variant in the fibrillin 1 (FBN1) gene.从一位马凡综合征患者的诱导多能干细胞(hiPSC)中生成 CRISPR/Cas9 校正的 hiPSC(NCCDFWi001-A-1),该患者的纤维连接蛋白 1(FBN1)基因中存在杂合 c.2613A>C 变异。
Stem Cell Res. 2021 Oct;56:102543. doi: 10.1016/j.scr.2021.102543. Epub 2021 Sep 20.
2
Generation of a human induced pluripotent stem cell line (NCCDFWi001-A) from a Marfan syndrome patient carrying two FBN1 variants (c.2613A > C and c.684_736 + 4del).从一名携带两个FBN1变体(c.2613A>C和c.684_736 + 4del)的马凡综合征患者中生成人诱导多能干细胞系(NCCDFWi001-A)。
Stem Cell Res. 2020 Jan;42:101690. doi: 10.1016/j.scr.2019.101690. Epub 2019 Dec 18.
3
Generation of human induced pluripotent stem cell line UGENTi001-A from a patient with Marfan syndrome carrying a heterozygous c.7754 T > C variant in FBN1 and the isogenic control UGENT001-A-1 using CRISPR/Cas9 editing.利用CRISPR/Cas9编辑技术,从一名患有马凡综合征且FBN1基因存在杂合c.7754 T>C变异的患者中生成人诱导多能干细胞系UGENTi001-A以及同基因对照UGENT001-A-1。
Stem Cell Res. 2023 Mar;67:103036. doi: 10.1016/j.scr.2023.103036. Epub 2023 Jan 25.
4
Generation of a human iPSC line from a patient with Marfan syndrome caused by mutation in FBN1.从一名因FBN1基因突变导致马凡综合征的患者身上生成人诱导多能干细胞系。
Stem Cell Res. 2019 Apr;36:101414. doi: 10.1016/j.scr.2019.101414. Epub 2019 Feb 27.
5
Generation of a human iPSC line QDMHi001-A from a patient with Marfan syndrome carrying a heterozygous c.6772 T > C variant in FBN1.从一名患有马凡综合征且在原纤蛋白-1(FBN1)基因中携带杂合c.6772 T>C变异的患者身上生成人类诱导多能干细胞系QDMHi001-A。
Stem Cell Res. 2021 Jul;54:102390. doi: 10.1016/j.scr.2021.102390. Epub 2021 May 16.
6
Reprogramming of a human induced pluripotent stem cell line from a Marfan syndrome patient harboring a heterozygous mutation of c.2939G > A in FBN1 gene.从一名患有马凡综合征的患者身上重编程建立人诱导多能干细胞系,该患者的原纤维蛋白1(FBN1)基因存在杂合突变c.2939G>A 。
Stem Cell Res. 2021 Mar;51:102163. doi: 10.1016/j.scr.2021.102163. Epub 2021 Jan 8.
7
Generation of an induced pluripotent stem cell (iPSC) line of a Marfan syndrome patient with a pathogenic FBN1 c.5372G > A (p.Cys1791Tyr) variant.生成一位马凡综合征患者的诱导多能干细胞 (iPSC) 系,该患者携带致病性 FBN1 c.5372G > A (p.Cys1791Tyr) 变异。
Stem Cell Res. 2023 Apr;68:103050. doi: 10.1016/j.scr.2023.103050. Epub 2023 Feb 15.
8
Generation of an induced pluripotent stem cell line, JHUi005-A, from a Marfan Syndrome patient harboring a pathogenic c.3338-2A>C intronic splicing variant.从一位携带致病性 c.3338-2A>C 内含子剪接变异的马凡综合征患者中生成诱导多能干细胞系 JHUi005-A。
Stem Cell Res. 2024 Sep;79:103475. doi: 10.1016/j.scr.2024.103475. Epub 2024 Jun 24.
9
Generation of Marfan patient specific iPSCs (ICSSUi001-A) carrying a novel heterozygous mutation in FBN1 gene.携带FBN1基因新型杂合突变的马凡氏综合征患者特异性诱导多能干细胞(ICSSUi001-A)的生成。
Stem Cell Res. 2022 Apr;60:102720. doi: 10.1016/j.scr.2022.102720. Epub 2022 Feb 24.
10
Generation of Marfan syndrome-specific induced pluripotent stem cells harboring FBN1 mutations.生成携带有 FBN1 突变的马凡综合征特异性诱导多能干细胞。
Stem Cell Res. 2024 Oct;80:103518. doi: 10.1016/j.scr.2024.103518. Epub 2024 Jul 29.

引用本文的文献

1
Therapeutic Opportunities of Marfan Syndrome: Current Perspectives.马凡综合征的治疗机遇:当前观点
Drug Des Devel Ther. 2025 Aug 26;19:7365-7379. doi: 10.2147/DDDT.S523571. eCollection 2025.
2
Human stem cell models for Marfan syndrome: a .马凡综合征的人类干细胞模型:一种……
Front Cell Dev Biol. 2025 Jan 3;12:1498669. doi: 10.3389/fcell.2024.1498669. eCollection 2024.
3
Translational potential of hiPSCs in predictive modeling of heart development and disease.人诱导多能干细胞在心脏发育和疾病预测模型中的转化潜力。
Birth Defects Res. 2022 Oct 1;114(16):926-947. doi: 10.1002/bdr2.1999. Epub 2022 Mar 9.